Potential role of lamivudine (3TC) in the clearance of chronic hepatitis B virus infection in a patient coinfected with human immunodeficiency virus type I

Clinical Infectious Diseases

Volumn 23, Issue 3, 1996, Pages 638-639

  Schnittman, Steven M ^a   Pierce, Phillip F ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; DIDANOSINE; HEPATITIS B VACCINE; LAMIVUDINE; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CASE REPORT; DRUG CLEARANCE; DRUG MECHANISM; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INFECTIVITY; VIRUS VIRULENCE;

EID: 0029788155     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/23.3.638     Document Type: Article

References (5)

1. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991;163:1138-40.
2. Hadler SC, Judson FN, O'Malley PM, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991;163:454-9.
3. Benhamou Y, Dohin E, Lunel-Fabiani F, et al. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 1995;345:396-7.
4. Chang CN, Doong SL, Zhou JH, et al. Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2′,3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. J Biol Chem 1992;267:13938.
5. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.